Two Sigma Advisers’s Relmada Therapeutics RLMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $15.1K | Sell |
25,100
-262,900
| -91% | -$158K | ﹤0.01% | 2292 |
|
|
2025
Q1 | $77.8K | Buy |
288,000
+89,100
| +45% | +$24.1K | ﹤0.01% | 2272 |
|
|
2024
Q4 | $103K | Sell |
198,900
-43,600
| -18% | -$22.7K | ﹤0.01% | 2217 |
|
|
2024
Q3 | $786K | Sell |
242,500
-50,000
| -17% | -$162K | ﹤0.01% | 1520 |
|
|
2024
Q2 | $878K | Sell |
292,500
-33,700
| -10% | -$101K | ﹤0.01% | 1615 |
|
|
2024
Q1 | $1.52M | Sell |
326,200
-2,100
| -0.6% | -$9.77K | ﹤0.01% | 1367 |
|
|
2023
Q4 | $1.36M | Buy |
328,300
+163,900
| +100% | +$679K | ﹤0.01% | 1480 |
|
|
2023
Q3 | $493K | Sell |
164,400
-81,300
| -33% | -$244K | ﹤0.01% | 1797 |
|
|
2023
Q2 | $604K | Sell |
245,700
-111,900
| -31% | -$275K | ﹤0.01% | 1742 |
|
|
2023
Q1 | $808K | Buy |
357,600
+34,500
| +11% | +$78K | ﹤0.01% | 1738 |
|
|
2022
Q4 | $1.13M | Buy |
323,100
+301,600
| +1,403% | +$1.05M | ﹤0.01% | 1519 |
|
|
2022
Q3 | $796K | Buy |
+21,500
| New | +$796K | ﹤0.01% | 1640 |
|